GlaxoSmithKline and its subsidiary Human Genome Sciences not only won the US FDA's OK to market raxibacumab in combination with antibacterials as a treatment for adults and pediatric patients with inhalational anthrax, the companies also were granted approval to sell the medicine as a preventive therapy when alternative treatments are not available or appropriate.
GSK/HGS win US FDA OK for raxibacumab as 1st mAb in anthrax
GlaxoSmithKline and its subsidiary Human Genome Sciences not only won the US FDA's OK to market raxibacumab in combination with antibacterials as a treatment for adults and pediatric patients with inhalational anthrax, the companies also were granted approval to sell the medicine as a preventive therapy when alternative treatments are not available or appropriate.
More from Anti-infective
• By
The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.
• By
Professor Anil Koul shares vignettes of his life and career trajectory, a captivating mix of hope, science and destiny that took him to the lab of eminent cancer biologist Alex Ullrich at the Max Planck Institute and also saw him contribute to the development of breakthrough TB drug bedaquiline. He also talks about Medicine 3.0 and the intersection of science and spirituality.
• By
The company is developing doravirine and islatravir together as an alternative to therapies containing integrase inhibitors, like Biktarvy, especially as HIV patients age.
• By
The two companies were among those presenting data at CROI that highlighted the next frontiers of competition in the HIV space.
More from Therapeutic Category
• By
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
• By
The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.
• By
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.